Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. The company is headquartered in Beijing, Beijing and currently employs 1,306 full-time employees. The company went IPO on 2022-09-01. The firm utilizes its self-developed RenMice fully human antibody and T-cell receptor (TCR) mouse platform for large-scale drug discovery and development targeting potential drug targets in the human body. The Company’s main businesses include the sale of innovative animal models, pre-clinical pharmacology and efficacy evaluation services, and antibody development. The firm is also engaged in the provision of gene-editing services. The firm operates its businesses in the domestic market and overseas markets.
02315.HK stock price ended at $53.5 on 金曜日, after rising 0.94%
On the latest trading day Feb 13, 2026, the stock price of 02315.HK rose by 0.94%, climbing from $53.00 to $53.50. During the session, the stock saw a volatility of 7.36%, with prices oscillating between a daily low of $50.95 and a high of $54.70. Notably, trading volume dropped by 319.2K shares on the last day despite the price increase, which may signal a potential uptick in risk in the near term. A total of 1.3M shares were traded, equating to a market value of approximately $5.7B.